[1] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023,41(1) : 3-28.
[2] Guo J T, Guo H. Metabolism and function of hepatitis B virus cccDNA: implications for the development of cccDNA-targeting antiviral therapeutics[J]. Antiviral Res, 2015,122:91-100.
[3] Li J, Hu C, Chen Y, et al. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B[J]. BMC Infect Dis, 2021,21(1):567.
[4] Dandri M, Petersen J. cccDNA maintenance in chronic hepatitis B-targeting the matrix of viral replication[J]. Infect Drug Resist, 2020,13:3873-3886.
[5] Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J]. Gut, 2015,64(12):1972-1984.
[6] 丁霞, 廖桂婵, 夏牧晔, 等. 探讨长期核苷(酸)类药物治疗慢性乙型肝炎患者停药后复发的影响因素[J]. 新发传染病电子杂志, 2019,4(1):52-55.
[7] Lu F, Wang J, Chen X, et al. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs[J]. Front Med, 2017,11(4):502-508.
[8] Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 2016,65(4):700-710.
[9] Jung K S, Park J Y, Chon Y E, et al. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients[J]. J Gastroenterol, 2016,51(8):830-839.
[10] Wang J, Sheng Q, Ding Y, et al. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient[J]. J Hepatol, 2018,68(4):847-849.
[11] Shen S, Xie Z, Cai D, et al. Biogenesis and molecular characteristics of serum hepatitis B virus RNA[J]. PLoS Pathog, 2020,16(10):e1008945.
[12] Stadelmayer B, Diederichs A, Chapus F, et al. Full-length 5′RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum[J]. J Hepatol, 2020,73(1):40-51.
[13] Bai L, Zhang X, Kozlowski M, et al. Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsid-antibody complexes in addition to virions in chronic hepatitis B patients[J]. J Virol, 2018,92(24).
[14] Lam A M, Ren S, Espiritu C, et al. Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants[J]. Antimicrob Agents Chemother, 2017,61(8):e00680-17.
[15] Prakash K, Rydell G E, Larsson S B, et al. High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles[J]. Virol J, 2018,15(1):86.
[16] Jansen L, Kootstra N A, van Dort K A, et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues[J]. J Infect Dis, 2016,213(2):224-232.
[17] Deng R, Liu S, Shen S, et al. Circulating HBV RNA: from biology to clinical applications[J]. Hepatology, 2022,76(5):1520-1530.
[18] van Bommel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J]. Hepatology, 2015,61(1):66-76.
[19] Brakenhoff S M, de Man R A, Boonstra A, et al. Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss[J]. Aliment Pharmacol Ther, 2021,53(2):314-320.
[20] 张缈曲, 张琪然, 张寒悦, 等. 一种新型乙型肝炎病毒RNA定量检测方法的临床检测性能评估[J]. 中华传染病杂志, 2020,38(12):782-785.
[21] Kojabad A A, Farzanehpour M, Galeh H, et al. Droplet digital PCR of viral DNA/RNA, current progress, challenges, and future perspectives[J]. J Med Virol, 2021,93(7):4182-4197.
[22] Limothai U, Chuaypen N, Poovorawan K, et al. Reverse transcriptase droplet digital PCR vs reverse transcriptase quantitative real-time PCR for serum HBV RNA quantification[J]. J Med Virol, 2020,92(12):3365-3372.
[23] Verbist B, Adriaensen E, Keersmaekers V, et al. Analyzing magnetic bead QuantiGene(R) Plex 2.0 gene expression data in high throughput mode using QGprofiler[J]. BMC Bioinformatics, 2019,20(1):378.
[24] Liu Y Y, Liang X S. Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA[J]. World J Hepatol, 2018,10(9):603-611.
[25] Cloherty G, Butler E, Kuhns M. Serum hepatitis B virus RNA as a potential diagnostic biomarker during chronic hepatitis B virus infection[J]. Clin Liver Dis (Hoboken), 2019,13(3):90-92.
[26] Wang Y, Liu Y, Liao H, et al. Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients[J]. Int J Med Sci, 2022,19(5):858-866.
[27] Wang J, Yu Y, Li G, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients[J]. J Hepatol, 2017.
[28] Huang H, Wang J, Li W, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals[J]. J Clin Virol, 2018,99-100:71-78.
[29] Liao H, Liu Y, Li X, et al. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy[J]. Antivir Ther, 2019,24(2):105-115.
[30] Jia W, Zhu M Q, Qi X, et al. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a[J]. Virol J, 2019,16(1):61.
[31] Huang C, Li Q, Xu W, et al. Serum HBV RNA levels predict significant liver fibrosis in patients with chronic HBV infection[J]. Discov Med, 2020,29(157):119-128.
[32] Wang J, Yu Y, Li G, et al. Natural history of serum HBV-RNA in chronic HBV infection[J]. J Viral Hepat, 2018,25(9):1038-1047.
[33] Zhang M, Li G, Shang J, et al. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study[J]. Hepatol Int, 2020,14(2):212-224.
[34] Farag M S, van Campenhout M, Pfefferkorn M, et al. Hepatitis B virus RNA as early predictor for response to pegylated interferon alpha in hbeag-negative chronic hepatitis B[J]. Clin Infect Dis, 2021,72(2):202-211.
[35] Limothai U, Chuaypen N, Poovorawan K, et al. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B[J]. J Viral Hepat, 2019,26(12):1481-1488.
[36] Xia M, Chi H, Wu Y, et al. Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment[J]. Aliment Pharmacol Ther, 2021,54(5):709-714.
[37] Luo H, Tan N, Kang Q, et al. Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues[J]. J Viral Hepat, 2020,27(3):323-328.
[38] Chan H, Chan F, Hui A J, et al. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study[J]. J Viral Hepat, 2019,26(1):126-135.
[39] 刘燕娜, 樊蓉, 杨瑞锋, 等. 慢性HBV感染者血清HBV RNA检测及临床应用的专家共识[J]. 中华肝脏病杂志, 2022,30(5): 505-512.
[40] Ghany M G, King W C, Lisker-Melman M, et al. Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America[J]. Hepatology, 2021,74(5):2395-2409.
[41] Mak L Y, Cloherty G, Wong D K, et al. HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy[J]. Hepatology, 2021,73(6):2167-2179.
[42] Liu Y, Jiang M, Xue J, et al. Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection[J]. BMC Gastroenterol, 2019,19(1):53.
[43] Fan R, Peng J, Xie Q, et al. Combining hepatitis B virus RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in hepatitis B e antigen-positive patients with chronic hepatitis B[J]. J Infect Dis, 2020,222(4):611-618. |
